Frankfurt - Delayed Quote EUR

Telo Genomics Corp. (3D0A.F)

0.0025 -0.0180 (-87.80%)

As of 8:02:39 AM GMT+1. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

TELO Genomics Expands Multi-Center Clinical Studies to Advance Comparative Validation of TELO-MRD Against Next-Generation Sequencing

TMX Newsfile 4d ago

TELO.V

ADPT

TDSGF
Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing

TMX Newsfile 1mo ago

TELO.V

TDSGF

3D0A.F
-87.80%
Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse

TMX Newsfile 1mo ago

TELO.V

3D0A.F
-87.80%
TDSGF
Telo Genomics Grants Stock Options

TMX Newsfile 2mo ago

TELO.V

3D0A.F
-87.80%
TDSGF
Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment

TMX Newsfile 3mo ago

TELO.V

TDSGF

3D0A.F
-87.80%
Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma

TMX Newsfile 3mo ago

TELO.V

TDSGF

3D0A.F
-87.80%
Telo Genomics Announces Termination of Investor Relations Agreement

TMX Newsfile 4mo ago

TELO.V

3D0A.F
-87.80%
TDSGF
Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma

TMX Newsfile 6mo ago

TELO.V

TDSGF

TELO
Telo Genomics Announces Appointment of John Price as Chief Financial Officer

TMX Newsfile 8mo ago

TDSGF

IONM

FIZZ
Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing

GlobeNewswire 10mo ago

NMHI

CLOQ

TDSGF
Small Cap Growth Virtual Investor Conference Agenda Announced for December 9th

GlobeNewswire 10mo ago

ROOOF

TDSGF

CCDSF

Performance Overview

Return	3D0A.F	S&P/TSX Composite index (^GSPTSE)
YTD	--	+12.35%
1-Year	-44.44%	+18.31%
3-Year	-97.84%	+80.59%

U.S. markets open in 4h 32m

Telo Genomics Corp. (3D0A.F)

TELO Genomics Expands Multi-Center Clinical Studies to Advance Comparative Validation of TELO-MRD Against Next-Generation Sequencing

Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing

Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse

Telo Genomics Grants Stock Options

Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment

Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma

Telo Genomics Announces Termination of Investor Relations Agreement

Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma

Telo Genomics Announces Appointment of John Price as Chief Financial Officer

Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing

Small Cap Growth Virtual Investor Conference Agenda Announced for December 9th